PSMA-Targeted Radiopharmaceuticals for Imaging and Therapy

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Science

Background:

• Prostate-specific membrane antigen (PSMA) is a highly promising molecular target in nuclear medicine.
• PSMA is overexpressed on prostate cancer cells, correlating with tumor stage and progression, particularly in advanced and metastatic disease.

Purpose of the Study:

• To provide an overview of radiopharmaceuticals targeting PSMA that have achieved widespread clinical application.
• To discuss recently introduced concepts in PSMA-tracer development, such as those with increased plasma protein binding.

Main Methods:

• Review of existing literature on PSMA-targeted radiopharmaceuticals.
• Analysis of characteristics of clinically applied radiotracers.
• Discussion of novel PSMA-tracer concepts.

Main Results:

• Small molecule inhibitors with high affinity to PSMA have largely replaced earlier monoclonal antibody probes.
• Numerous PSMA-targeting radiopharmaceuticals, including [18F]FDCFPyL, [18F]PSMA-1007, [68Ga]PSMA-HBED, [177Lu]PSMA-617, and others, have been developed and clinically applied.
• Research is advancing towards PSMA-tracers with enhanced properties like increased plasma protein binding.

Conclusions:

• PSMA-targeted radiopharmaceuticals are crucial tools for prostate cancer detection and therapy.
• The focus has shifted to small molecule PSMA inhibitors for improved tumor uptake and excretion.
• Ongoing research continues to refine PSMA-tracer technology for enhanced clinical utility.